Novo Nordisk acquires Cardior for 1 billion euros to accelerate its layout in the cardiovascular field
Ty奇葩罗牛山831
发表于 2024-3-26 12:50:58
1185
0
0
On Monday local time, Danish pharmaceutical giant Novo Nordisk announced that it will acquire Cardio Pharmaceuticals for 1.03 billion euros, and the two companies have reached a related acquisition agreement. At present, Novo Nordisk is expanding beyond the market of diabetes and weight loss, and accelerating the layout of its product lines for cardiovascular diseases.
In recent years, Novo Nordisk has achieved great success because of its star weight loss drugs and diabetes treatment drugs (Ozempic and Wegovy). These drugs are not only very effective in regulating blood sugar and helping patients lose weight, but also produce additional health benefits, such as reducing the risk of stroke and heart disease, and slowing down the progress of kidney disease.
Based on these findings, Novo Nordisk announced this month that the company will invest significant resources in the field of cardiovascular disease to establish a competitive track.
David Moore, Executive Vice President of Enterprise Development at Novo Nordisk, stated that the company will seek to fully develop its first independent cardiovascular disease drug, Ziltivekimab. It is reported that the drug is in the phase III research and development stage and is used to treat atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).
Novo Nordisk issued a statement on Monday stating, "The acquisition of Cardior is an important step for Novo Nordisk to expand its business scope and influence in the field of cardiovascular disease."
Cardior is a German biopharmaceutical company founded in 2016, focusing on the development of non coding RNA (ncRNA) based heart failure treatments and preventive drugs. NcRNAs include microRNAs and lncRNAs, which regulate signaling pathways within molecular cells, leading to myocardial remodeling and heart failure.
It is reported that the lead compound CDR132L of Cardior can improve heart function, prevent and partially reverse the disease progression of heart failure patients, and is currently in the phase II clinical development stage for treating heart failure. Novo Nordisk plans to launch follow-up experiments after the acquisition.
The transaction is expected to be completed in the second quarter of 2024. This funding will come from financial reserves, so it will not affect Novo Nordisk's profit guidance for 2024 or ongoing stock repurchases.
Martin Holst Lange, Executive Vice President of Development at Novo Nordisk, said, "The scientific work carried out by the Cardior team has left a deep impression on us, especially the CDR132L, which has a unique mode of action and may become a first-class treatment for cardiovascular disease, preventing or partially reversing the disease progression of heart failure patients."
Dr. Claudia Ulbrich, CEO and co-founder of Cardior, said, "This acquisition reflects the transformative potential of CDR132L as a treatment for cardiovascular disease. With its profound clinical and business knowledge, as well as its resources, Novo Nordisk can accelerate our later development plans, including through larger scale registration research, making it an ideal partner. We look forward to CDR132L's early market approval."
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Ferrari's first electric car is priced at least 500000 euros, and the second electric vehicle model is under development
- Investment experts firmly believe that Nvidia's narrative prospects: short-term fluctuations will not affect long-term layout
- "Capitol Hill Stock God" moves repeatedly! Pelosi's layout of Broadcom and pursuit of Nvidia
- GSK is betting 1.45 billion euros on the imminent outbreak of cross generational business opportunities in mRNA therapy categories?
- Stellantis Group's net profit for the first half of the year was 5.65 billion euros, a year-on-year decrease of 48%
- Stellantis Group's net profit for the first half of the year was 5.65 billion euros, a year-on-year decrease of 48%
- Accelerate the pace of globalization! Single quarter revenue growth of 16%, Cainiao's "circle focus" layout overseas local network
- Monster Charging CEO Cai Guangyuan: Actively exploring the layout of shared charging business overseas
- Trillion giants suddenly face negative news! Uber fined 290 million euros by Dutch regulatory authorities
- Shanghai CDC says flu vaccine reserves are sufficient, industry estimates Sanofi's suspension of vaccination will result in losses of at least hundreds of millions of euros
-
过去一周的时间里,有关苹果微信“二选一”的话题持续霸占各个平台热搜,甚至有媒体还在微博发起了“如果苹果微信二选一,你选择iPhone还是微信?”的投票,当然结果是微信取得了压倒性的胜利。 从最新的 ...
- lub_pig
- 昨天 17:05
- 支持
- 反对
- 回复
- 收藏
-
今日,特斯拉AI团队发布产品路线图,其中,预计2025年第一季度在中国和欧洲推出完全自动驾驶(FSD),但仍有待监管批准。 自2016年以来,马斯克一直在探索特斯拉的FSD自动驾驶方案。2024年,特斯拉FSD V12 ...
- seisei
- 前天 16:32
- 支持
- 反对
- 回复
- 收藏
-
【全球市场】1、道指跌0.54%,纳指涨0.25%,标普跌0.30%。2、特斯拉涨近5%,亚马逊涨超2%。3、纳斯达克中国金龙指数涨0.88%,蔚来涨超14%。
- wishii
- 昨天 22:03
- 支持
- 反对
- 回复
- 收藏
-
【ASML CEO回应对华出口限制:会有更多应对措施】当地时间9月4日,荷兰计算机芯片设备供应商ASML首席执行官Christophe Fouquet在花旗银行的一场会议上表示,美国限制ASML对华出口是出于“经济动机”。他预计该公司应 ...
- mbgg2797
- 前天 09:15
- 支持
- 反对
- 回复
- 收藏